Table 2 Demographic and Clinical Characteristics in All Patients
Patients | |
|---|---|
(N = 410) | |
Demographic characteristics | |
Sex, n (%) | |
Female | 390 (95.1) |
Male | 20 (4.9) |
Age at diagnosis, mean ± SD [median] | 52 (12.6) [50.0] |
18–44 years | 137 (33.4) |
45–64 years | 201 (49.0) |
65+ years | 72 (17.6) |
Age at diagnosis, categories according to Wood et al.a | |
< 40 years | 70 (17.1) |
40–49 years | 128 (31.2) |
50–59 years | 91 (22.2) |
60–69 years | 85 (20.7) |
≥ 70 years | 36 (8.8) |
Race, n (%) | |
White | 302 (73.7) |
Black or African American | 69 (16.8) |
Asian | 27 (6.6) |
Native Hawaiian or Other Pacific Islander | 1 (0.2) |
Other | 11 (2.7) |
Ethnicity, n (%) | |
Hispanic/Latino | 43 (10.5) |
Non-Hispanic/Latino | 354 (86.3) |
Unknown | 13 (3.2) |
Ashkenazi Jewish ancestry, n (%) | |
Yes | 78 (19.0) |
No | 313 (76.3) |
Unknown | 19 (4.6) |
Breast cancer pathology | |
Cancer stage at diagnosis, n (%) | |
Stage 0-III (non-metastatic) | 286 (69.8) |
Stage IV (metastatic) | 124 (30.2) |
ER status, n (%) | |
Positive | 244 (59.5) |
Negative | 166 (40.5) |
PR status, n (%) | |
Positive | 206 (50.2) |
Negative | 204 (49.8) |
HER2 status, n (%) | |
Positive | 73 (17.8) |
Negative | 337 (82.2) |
Triple negative, n (%) | 126 (30.7) |
Nottingham combined histologic grade, n (%) | |
GX (undetermined grade) | 2 (0.5) |
G1 | 43 (10.5) |
G2 | 171 (41.7) |
G3 | 192 (46.8) |
Unknown | 2 (0.5) |
Additional primary breast cancer, n (%) | |
Yes | 27 (6.6) |
No | 382 (93.2) |
Unknown | 1 (0.2) |
Additional clinical information assessed in female patients | (N = 390) |
Treated for other cancerb, n (%) | |
Yes, Ovarian carcinoma | 18 (4.6) |
Yes, Other | 10 (2.6) |
No | 362 (92.8) |
Postmenopausal at diagnosis, n (%) | |
Yes | 185 (47.4) |
No | 201 (51.5) |
Unknown | 4 (1.0) |